Obiettivo Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues. Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting millions of people worldwide. Current treatment strategies are not successful because the precise etiology unclear. It is increasingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium has the ambition to educate a group of next-generation scientists that master genetics, epigenetics, target discovery, pharmacology, preclinical validation and regulatory issues, and at the same time have a good understanding of clinical implementations of the drug pipeline of our pharmaceutical partner GSK. GSK is one of the world's leading research-based pharmaceutical and healthcare companies that aims to team up with academic partners in EPIMAC through its dedicated discovery performance unit named EpiNova in conjunction with 2 immuno-pharmacology units. An SME specializing in epigenetic compound targeting to inflammatory cells, Chroma Therapeutics, will contribute technology to EPIMAC. EPIMAC will educate and train these scientists by providing them with a versatile and multidisciplinary doctoral program, allowing them to become excellent scientists skilled to overcome the current challenges in IBD. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineimmunologynatural sciencesbiological sciencesgeneticsepigenetics Parole chiave Gastroenterology Inflammatory Bowel Diseases Drug Development Programma(i) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers Argomento(i) MSCA-ITN-2014-EID - Marie Skłodowska-Curie Innovative Training Networks (ITN-EID) Invito a presentare proposte H2020-MSCA-ITN-2014 Vedi altri progetti per questo bando Meccanismo di finanziamento MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN) Coordinatore AMC MEDICAL RESEARCH BV Contribution nette de l'UE € 1 021 497,12 Indirizzo MEIBERGDREEF 9 1105AZ Amsterdam Zuidoost Paesi Bassi Mostra sulla mappa Regione West-Nederland Noord-Holland Groot-Amsterdam Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 021 497,12 Partecipanti (2) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. Regno Unito Contribution nette de l'UE € 273 287,88 Indirizzo Great West Road 980 TW89GS Brentford Mostra sulla mappa Regione London Outer London — West and North West Hounslow and Richmond upon Thames Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 273 287,88 ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Paesi Bassi Contribution nette de l'UE € 0,00 Indirizzo MEIBERGDREEF 15 1105AZ Amsterdam Mostra sulla mappa Regione West-Nederland Noord-Holland Groot-Amsterdam Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale Nessun dato Partner (2) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto Partner Le organizzazioni partner contribuiscono all’attuazione dell’azione, ma non sottoscrivono l’accordo di sovvenzione. UNIVERSITAIR MEDISCH CENTRUM UTRECHT Paesi Bassi Contribution nette de l'UE € 0,00 Indirizzo HEIDELBERGLAAN 100 3584 CX Utrecht Mostra sulla mappa Regione West-Nederland Utrecht Utrecht Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale Nessun dato Partner Le organizzazioni partner contribuiscono all’attuazione dell’azione, ma non sottoscrivono l’accordo di sovvenzione. Eureka Contribution nette de l'UE € 0,00 Indirizzo Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale Nessun dato